Overview
Palatin Technologies, Inc. (NYSE Amex: PTN) is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Our programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems.
Our primary product in development is bremelanotide for the treatment of female sexual dysfunction in premenopausal women. In addition, we have development programs or drug candidates for erectile dysfunction, pulmonary diseases, heart failure, obesity and inflammatory diseases.
The melanocortin system is involved in a large and diverse number of physiologic functions, and therapeutic agents modulating this system may have the potential to treat a variety of conditions and diseases, including sexual dysfunction, obesity and diabetes, and inflammation-related and dermatologic diseases.
The natriuretic peptide receptor system has numerous pulmonary and cardiovascular functions, and therapeutic agents modulating this system may be useful in treatment of severe asthma, heart failure, and other cardiovascular diseases.
Palatin has a collaboration with AstraZeneca (NYSE: AZN) on compounds that target melanocortin receptors for treatment of obesity, diabetes and related metabolic syndrome.
Product Portfolio
Our lead product in development is bremelanotide, a peptide melanocortin receptor agonist, for treatment of female sexual dysfunction. Ongoing Phase 2B clinical trials are evaluating safety and efficacy of bremelanotide in premenopausal women with female sexual dysfunction.
Our other product candidates include
- AZD-2820, a peptide melanocortin receptor partial agonist, which started Phase 1 clinical trials in the first half of 2011, under development by AstraZeneca under our research collaboration and global license on melanocortin receptor-based compounds for treating obesity and related metabolic syndrome.
- PL-3994, a peptidomimetic natriuretic peptide receptor A agonist, for treatment of severe asthma and other pulmonary diseases.
- PL-6983, a peptide melanocortin-4 receptor agonist, a back-up therapeutic for sexual dysfunction, including female sexual dysfunction.
|
